ID   KAPCA_HUMAN             Reviewed;         351 AA.
AC   P17612; Q32P54; Q9H2Y0; Q9NRB4; Q9NRH9;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   22-JUL-2015, entry version 181.
DE   RecName: Full=cAMP-dependent protein kinase catalytic subunit alpha;
DE            Short=PKA C-alpha;
DE            EC=2.7.11.11;
GN   Name=PRKACA; Synonyms=PKACA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2843813; DOI=10.1093/nar/16.16.8189;
RA   Maldonado F., Hanks S.K.;
RT   "A cDNA clone encoding human cAMP-dependent protein kinase catalytic
RT   subunit C alpha.";
RL   Nucleic Acids Res. 16:8189-8190(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-189 (ISOFORM 2), SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=10906071; DOI=10.1095/biolreprod63.2.607;
RA   Reinton N., Orstavik S., Haugen T.B., Jahnsen T., Tasken K.,
RA   Skalhegg B.S.;
RT   "A novel isoform of human cyclic 3',5'-adenosine monophosphate-
RT   dependent protein kinase, c alpha-s, localizes to sperm midpiece.";
RL   Biol. Reprod. 63:607-611(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-152 (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=10982398; DOI=10.1091/mbc.11.9.3031;
RA   San Agustin J.T., Wilkerson C.G., Witman G.B.;
RT   "The unique catalytic subunit of sperm cAMP-dependent protein kinase
RT   is the product of an alternative C-alpha mRNA expressed specifically
RT   in spermatogenic cells.";
RL   Mol. Biol. Cell 11:3031-3044(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-39 (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=10841548; DOI=10.1073/pnas.97.12.6433;
RA   Desseyn J.-L., Burton K.A., McKnight G.S.;
RT   "Expression of a nonmyristylated variant of the catalytic subunit of
RT   protein kinase A during male germ-cell development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6433-6438(2000).
RN   [9]
RP   AUTOPHOSPHORYLATION, PHOSPHORYLATION AT THR-196, PHOSPHORYLATION AT
RP   THR-198 BY PDK1, AND MUTAGENESIS OF ARG-195; GLY-201 AND THR-202.
RX   PubMed=12372837; DOI=10.1074/jbc.M204970200;
RA   Moore M.J., Kanter J.R., Jones K.C., Taylor S.S.;
RT   "Phosphorylation of the catalytic subunit of protein kinase A.
RT   Autophosphorylation versus phosphorylation by phosphoinositide-
RT   dependent kinase-1.";
RL   J. Biol. Chem. 277:47878-47884(2002).
RN   [10]
RP   INTERACTION WITH RAB13.
RX   PubMed=15096524; DOI=10.1083/jcb.200312118;
RA   Koehler K., Louvard D., Zahraoui A.;
RT   "Rab13 regulates PKA signaling during tight junction assembly.";
RL   J. Cell Biol. 165:175-180(2004).
RN   [11]
RP   FUNCTION AS NFKB1 KINASE.
RX   PubMed=15642694; DOI=10.1074/jbc.M412180200;
RA   Guan H., Hou S., Ricciardi R.P.;
RT   "DNA binding of repressor nuclear factor-kappaB p50/p50 depends on
RT   phosphorylation of Ser337 by the protein kinase A catalytic subunit.";
RL   J. Biol. Chem. 280:9957-9962(2005).
RN   [12]
RP   FUNCTION AS CLDN3 KINASE.
RX   PubMed=15905176; DOI=10.1074/jbc.M502003200;
RA   D'Souza T., Agarwal R., Morin P.J.;
RT   "Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent
RT   protein kinase regulates tight junction barrier function in ovarian
RT   cancer cells.";
RL   J. Biol. Chem. 280:26233-26240(2005).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH AICDA.
RX   PubMed=16387847; DOI=10.1073/pnas.0509969103;
RA   Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R.;
RT   "PKA-mediated phosphorylation regulates the function of activation-
RT   induced deaminase (AID) in B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:395-400(2006).
RN   [14]
RP   FUNCTION IN PROTEASOME REGULATION, AND FUNCTION AS PSMC5/RPT6 KINASE.
RX   PubMed=17565987; DOI=10.1074/jbc.M702439200;
RA   Zhang F., Hu Y., Huang P., Toleman C.A., Paterson A.J., Kudlow J.E.;
RT   "Proteasome function is regulated by cyclic AMP-dependent protein
RT   kinase through phosphorylation of Rpt6.";
RL   J. Biol. Chem. 282:22460-22471(2007).
RN   [15]
RP   FUNCTION AS RYR2 KINASE.
RX   PubMed=17693412; DOI=10.1074/jbc.M703510200;
RA   Xiao B., Tian X., Xie W., Jones P.P., Cai S., Wang X., Jiang D.,
RA   Kong H., Zhang L., Chen K., Walsh M.P., Cheng H., Chen S.R.W.;
RT   "Functional consequence of protein kinase A-dependent phosphorylation
RT   of the cardiac ryanodine receptor: sensitization of store overload-
RT   induced Ca2+ release.";
RL   J. Biol. Chem. 282:30256-30264(2007).
RN   [16]
RP   PHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=17909264; DOI=10.1677/JME-07-0048;
RA   Ichikawa T., Horie-Inoue K., Ikeda K., Blumberg B., Inoue S.;
RT   "Vitamin K2 induces phosphorylation of protein kinase A and expression
RT   of novel target genes in osteoblastic cells.";
RL   J. Mol. Endocrinol. 39:239-247(2007).
RN   [17]
RP   FUNCTION AS ALPHA-DIFLUOROMETHYLORNITHINE ANTAGONIST.
RX   PubMed=17333334; DOI=10.1007/s10549-007-9536-5;
RA   Xu H., Washington S., Verderame M.F., Manni A.;
RT   "Activation of protein kinase A (PKA) signaling mitigates the
RT   antiproliferative and antiinvasive effects of alpha-
RT   difluoromethylornithine in breast cancer cells.";
RL   Breast Cancer Res. Treat. 107:63-70(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-49 AND SER-339, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH APOBEC3G.
RX   PubMed=18836454; DOI=10.1038/nsmb.1497;
RA   Shirakawa K., Takaori-Kondo A., Yokoyama M., Izumi T., Matsui M.,
RA   Io K., Sato T., Sato H., Uchiyama T.;
RT   "Phosphorylation of APOBEC3G by protein kinase A regulates its
RT   interaction with HIV-1 Vif.";
RL   Nat. Struct. Mol. Biol. 15:1184-1191(2008).
RN   [20]
RP   ENZYME REGULATION, AND MUTAGENESIS OF TYR-205.
RX   PubMed=18178622; DOI=10.1073/pnas.0709214104;
RA   Masterson L.R., Mascioni A., Traaseth N.J., Taylor S.S., Veglia G.;
RT   "Allosteric cooperativity in protein kinase A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:506-511(2008).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19210988; DOI=10.1016/j.yexcr.2008.12.026;
RA   Yan X., Walkiewicz M., Carlson J., Leiphon L., Grove B.;
RT   "Gravin dynamics regulates the subcellular distribution of PKA.";
RL   Exp. Cell Res. 315:1247-1259(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-339, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   FUNCTION IN PLATELETS, FUNCTION AS VASP KINASE, AND INTERACTION WITH
RP   NFKB1; NFKB2 AND NFKBIA.
RX   PubMed=20356841; DOI=10.1074/jbc.M109.077602;
RA   Gambaryan S., Kobsar A., Rukoyatkina N., Herterich S., Geiger J.,
RA   Smolenski A., Lohmann S.M., Walter U.;
RT   "Thrombin and collagen induce a feedback inhibitory signaling pathway
RT   in platelets involving dissociation of the catalytic subunit of
RT   protein kinase A from an NFkappaB-IkappaB complex.";
RL   J. Biol. Chem. 285:18352-18363(2010).
RN   [25]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION, AND ENZYME REGULATION.
RX   PubMed=19949837; DOI=10.1007/s11010-009-0344-6;
RA   Wang W., Zhang X., Zheng J., Yang J.;
RT   "High glucose stimulates adipogenic and inhibits osteogenic
RT   differentiation in MG-63 cells through cAMP/protein kinase
RT   A/extracellular signal-regulated kinase pathway.";
RL   Mol. Cell. Biochem. 338:115-122(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   FUNCTION AS RORA KINASE.
RX   PubMed=21514275; DOI=10.1016/j.bbrc.2011.04.046;
RA   Ermisch M., Firla B., Steinhilber D.;
RT   "Protein kinase A activates and phosphorylates ROR?4 in vitro and
RT   takes part in ROR? activation by CaMK-IV.";
RL   Biochem. Biophys. Res. Commun. 408:442-446(2011).
RN   [28]
RP   FUNCTION AS KINASE, TISSUE SPECIFICITY, AND INTERACTION WITH
RP   PRKAR1A/PKR1 AND PRKAR2A/PKR2.
RX   PubMed=21812984; DOI=10.1186/1471-2091-12-40;
RA   Vetter M.M., Zenn H.-M., Mendez E., van den Boom H., Herberg F.W.,
RA   Skaalhegg B.S.;
RT   "The testis-specific C?2 subunit of PKA is kinetically
RT   indistinguishable from the common C?1 subunit of PKA.";
RL   BMC Biochem. 12:40-40(2011).
RN   [29]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21423175; DOI=10.1038/ncb2209;
RA   Lignitto L., Carlucci A., Sepe M., Stefan E., Cuomo O., Nistico R.,
RA   Scorziello A., Savoia C., Garbi C., Annunziato L., Feliciello A.;
RT   "Control of PKA stability and signalling by the RING ligase praja2.";
RL   Nat. Cell Biol. 13:412-422(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-339, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   INVOLVEMENT IN PPNAD4, VARIANT PPNAD4 ARG-206, AND CHARACTERIZATION OF
RP   VARIANT PPNAD4 ARG-206.
RX   PubMed=24747643; DOI=10.1038/ng.2956;
RA   Goh G., Scholl U.I., Healy J.M., Choi M., Prasad M.L.,
RA   Nelson-Williams C., Kunstman J.W., Kuntsman J.W., Korah R.,
RA   Suttorp A.C., Dietrich D., Haase M., Willenberg H.S., Staalberg P.,
RA   Hellman P., Akerstroem G., Bjoerklund P., Carling T., Lifton R.P.;
RT   "Recurrent activating mutation in PRKACA in cortisol-producing adrenal
RT   tumors.";
RL   Nat. Genet. 46:613-617(2014).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 15-351, AND PHOSPHORYLATION
RP   AT THR-198 AND SER-339.
RX   PubMed=16765046; DOI=10.1016/j.bmcl.2006.05.092;
RA   Lin X., Murray J.M., Rico A.C., Wang M.X., Chu D.T., Zhou Y.,
RA   Del Rosario M., Kaufman S., Ma S., Fang E., Crawford K.,
RA   Jefferson A.B.;
RT   "Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for
RT   AKT: synthesis and SAR studies.";
RL   Bioorg. Med. Chem. Lett. 16:4163-4168(2006).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS), PHOSPHORYLATION AT THR-198 AND
RP   SER-339, AND ENZYME REGULATION.
RX   PubMed=20137943; DOI=10.1016/j.bmcl.2010.01.067;
RA   Zeng Q., Allen J.G., Bourbeau M.P., Wang X., Yao G., Tadesse S.,
RA   Rider J.T., Yuan C.C., Hong F.-T., Lee M.R., Zhang S., Lofgren J.A.,
RA   Freeman D.J., Yang S., Li C., Tominey E., Huang X., Hoffman D.,
RA   Yamane H.K., Fotsch C., Dominguez C., Hungate R., Zhang X.;
RT   "Azole-based inhibitors of AKT/PKB for the treatment of cancer.";
RL   Bioorg. Med. Chem. Lett. 20:1559-1564(2010).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS), PHOSPHORYLATION AT THR-198 AND
RP   SER-339, AND ENZYME REGULATION.
RX   PubMed=20481595; DOI=10.1021/jm1003842;
RA   Freeman-Cook K.D., Autry C., Borzillo G., Gordon D.,
RA   Barbacci-Tobin E., Bernardo V., Briere D., Clark T., Corbett M.,
RA   Jakubczak J., Kakar S., Knauth E., Lippa B., Luzzio M.J., Mansour M.,
RA   Martinelli G., Marx M., Nelson K., Pandit J., Rajamohan F.,
RA   Robinson S., Subramanyam C., Wei L., Wythes M., Morris J.;
RT   "Design of selective, ATP-competitive inhibitors of Akt.";
RL   J. Med. Chem. 53:4615-4622(2010).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH ADENOSINE
RP   ANALOG, PHOSPHORYLATION AT SER-11; THR-198 AND SER-339, AND ENZYME
RP   REGULATION.
RX   PubMed=20732331; DOI=10.1016/j.jmb.2010.08.028;
RA   Pflug A., Rogozina J., Lavogina D., Enkvist E., Uri A., Engh R.A.,
RA   Bossemeyer D.;
RT   "Diversity of bisubstrate binding modes of adenosine analogue-
RT   oligoarginine conjugates in protein kinase a and implications for
RT   protein substrate interactions.";
RL   J. Mol. Biol. 403:66-77(2010).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH AURORA KINASE
RP   INHIBITORS, PHOSPHORYLATION AT SER-11; THR-198 AND SER-339, AND
RP   MUTAGENESIS OF LYS-48; LEU-96; MET-121; VAL-124; GLN-182 AND THR-184.
RX   PubMed=21774789; DOI=10.1042/BJ20110592;
RA   Pflug A., de Oliveira T.M., Bossemeyer D., Engh R.A.;
RT   "Mutants of protein kinase A that mimic the ATP-binding site of Aurora
RT   kinase.";
RL   Biochem. J. 440:85-93(2011).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND PHOSPHORYLATION AT THR-198
RP   AND SER-339.
RA   Behnen J., Koester H., Ritschel T., Neudert G., Heine A., Klebe G.;
RT   "Experimental active site mapping as a starting point to fragment-
RT   based lead discovery.";
RL   Submitted (JUL-2010) to the PDB data bank.
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS).
RA   Koester H., Craan T., Brass S., Heine A., Klebe G.;
RT   "Fragment based drug design on PKA.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [39]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-41; GLN-46 AND CYS-264.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [40]
RP   VARIANT PPNAD4 ARG-206, AND CHARACTERIZATION OF VARIANT PPNAD4
RP   ARG-206.
RX   PubMed=24571724; DOI=10.1056/NEJMoa1310359;
RA   Beuschlein F., Fassnacht M., Assie G., Calebiro D., Stratakis C.A.,
RA   Osswald A., Ronchi C.L., Wieland T., Sbiera S., Faucz F.R., Schaak K.,
RA   Schmittfull A., Schwarzmayr T., Barreau O., Vezzosi D., Rizk-Rabin M.,
RA   Zabel U., Szarek E., Salpea P., Forlino A., Vetro A., Zuffardi O.,
RA   Kisker C., Diener S., Meitinger T., Lohse M.J., Reincke M.,
RA   Bertherat J., Strom T.M., Allolio B.;
RT   "Constitutive activation of PKA catalytic subunit in adrenal Cushing's
RT   syndrome.";
RL   N. Engl. J. Med. 370:1019-1028(2014).
RN   [41]
RP   VARIANT PPNAD4 ARG-206, AND CHARACTERIZATION OF VARIANT PPNAD4
RP   ARG-206.
RX   PubMed=24700472; DOI=10.1126/science.1249480;
RA   Cao Y., He M., Gao Z., Peng Y., Li Y., Li L., Zhou W., Li X.,
RA   Zhong X., Lei Y., Su T., Wang H., Jiang Y., Yang L., Wei W., Yang X.,
RA   Jiang X., Liu L., He J., Ye J., Wei Q., Li Y., Wang W., Wang J.,
RA   Ning G.;
RT   "Activating hotspot L205R mutation in PRKACA and adrenal Cushing's
RT   syndrome.";
RL   Science 344:913-917(2014).
RN   [42]
RP   VARIANT PPNAD4 ARG-206, AND CHARACTERIZATION OF VARIANT PPNAD4
RP   ARG-206.
RX   PubMed=24855271; DOI=10.1126/science.1252328;
RA   Sato Y., Maekawa S., Ishii R., Sanada M., Morikawa T., Shiraishi Y.,
RA   Yoshida K., Nagata Y., Sato-Otsubo A., Yoshizato T., Suzuki H.,
RA   Shiozawa Y., Kataoka K., Kon A., Aoki K., Chiba K., Tanaka H.,
RA   Kume H., Miyano S., Fukayama M., Nureki O., Homma Y., Ogawa S.;
RT   "Recurrent somatic mutations underlie corticotropin-independent
RT   Cushing's syndrome.";
RL   Science 344:917-920(2014).
CC   -!- FUNCTION: Phosphorylates a large number of substrates in the
CC       cytoplasm and the nucleus. Regulates the abundance of
CC       compartmentalized pools of its regulatory subunits through
CC       phosphorylation of PJA2 which binds and ubiquitinates these
CC       subunits, leading to their subsequent proteolysis. Phosphorylates
CC       CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP.
CC       RORA is activated by phosphorylation. Required for glucose-
CC       mediated adipogenic differentiation increase and osteogenic
CC       differentiation inhibition from osteoblasts. Involved in the
CC       regulation of platelets in response to thrombin and collagen;
CC       maintains circulating platelets in a resting state by
CC       phosphorylating proteins in numerous platelet inhibitory pathways
CC       when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-
CC       alpha (NFKBIA), but thrombin and collagen disrupt these complexes
CC       and free active PRKACA stimulates platelets and leads to platelet
CC       aggregation by phosphorylating VASP. Prevents the
CC       antiproliferative and anti-invasive effects of alpha-
CC       difluoromethylornithine in breast cancer cells when activated.
CC       RYR2 channel activity is potentiated by phosphorylation in
CC       presence of luminal Ca(2+), leading to reduced amplitude and
CC       increased frequency of store overload-induced Ca(2+) release
CC       (SOICR) characterized by an increased rate of Ca(2+) release and
CC       propagation velocity of spontaneous Ca(2+) waves, despite reduced
CC       wave amplitude and resting cytosolic Ca(2+). PSMC5/RPT6 activation
CC       by phosphorylation stimulates proteasome. Negatively regulates
CC       tight junctions (TJs) in ovarian cancer cells via CLDN3
CC       phosphorylation. NFKB1 phosphorylation promotes NF-kappa-B p50-p50
CC       DNA binding. Involved in embryonic development by down-regulating
CC       the Hedgehog (Hh) signaling pathway that determines embryo pattern
CC       formation and morphogenesis. Prevents meiosis resumption in
CC       prophase-arrested oocytes via CDC25B inactivation by
CC       phosphorylation. May also regulate rapid eye movement (REM) sleep
CC       in the pedunculopontine tegmental (PPT). Phosphorylates APOBEC3G
CC       and AICDA. Isoform 2 phosphorylates and activates ABL1 in sperm
CC       flagellum to promote spermatozoa capacitation.
CC       {ECO:0000269|PubMed:15642694, ECO:0000269|PubMed:15905176,
CC       ECO:0000269|PubMed:16387847, ECO:0000269|PubMed:17333334,
CC       ECO:0000269|PubMed:17565987, ECO:0000269|PubMed:17693412,
CC       ECO:0000269|PubMed:18836454, ECO:0000269|PubMed:19949837,
CC       ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:21423175,
CC       ECO:0000269|PubMed:21514275, ECO:0000269|PubMed:21812984}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Allosterically activated by various compounds,
CC       including ATP. Activated by cAMP; the nucleotide acts as a dynamic
CC       and allosteric activator by coupling the two lobes of apo PKA,
CC       enhancing the enzyme dynamics synchronously and priming it for
CC       catalysis. Inhibited by H89 (N-[2-[[3-(4-Bromophenyl)-2-
CC       propenyl]amino]ethyl]-5-isoquinolinesulfonamide), spiroindoline,
CC       azole-based inhibitors, (3s)-amino-aminomethylbenzamide analogs,
CC       ARC-1032 (6-{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
CC       dihydroxyoxolan-2-yl]formamido}-N-[(1R)-4-carbamimidamido-1-
CC       carbamoylbutyl]hexanamide), ARC-1034 (6-{[(2S,3S,4R,5R)-5-(6-
CC       amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]formamido}-N-[(1R)-
CC       4-carbamimidamido-1-{[(1R)-4-carbamimidamido-1-
CC       carbamoylbutyl]carbamoyl}butyl]hexanamide), ARC-582, ARC-902 (Adc-
CC       6-aminohexanoic acid-(D-Arg)(6)-NH(2)), ARC-1012 ((2R)-6-amino-2-
CC       (6-{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-
CC       2-yl]formamido}hexanamido)-N-(5-{[(1R)-4-carbamimidamido-1-{[(1R)-
CC       4-carbamimidamido-1-
CC       carbamoylbutyl]carbamoyl}butyl]carbamoyl}pentyl)hexanamide) and
CC       ARC-1039 (6-{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
CC       dihydroxyoxolan-2-yl]formamido}-N-[(1R)-1-[(5-{[(1R)-4-
CC       carbamimidamido-1-{[(1R)-4-carbamimidamido-1-
CC       carbamoylbutyl]carbamoyl}butyl]carbamoyl}pentyl)carbamoyl]ethyl]he
CC       xanamide). {ECO:0000269|PubMed:17909264,
CC       ECO:0000269|PubMed:18178622, ECO:0000269|PubMed:19949837,
CC       ECO:0000269|PubMed:20137943, ECO:0000269|PubMed:20481595,
CC       ECO:0000269|PubMed:20732331}.
CC   -!- SUBUNIT: A number of inactive tetrameric holoenzymes are produced
CC       by the combination of homo- or heterodimers of the different
CC       regulatory subunits associated with two catalytic subunits. cAMP
CC       causes the dissociation of the inactive holoenzyme into a dimer of
CC       regulatory subunits bound to four cAMP and two free monomeric
CC       catalytic subunits. The cAMP-dependent protein kinase catalytic
CC       subunit binds PJA2. Both isoforms 1 and 2 forms activate cAMP-
CC       sensitive PKAI and PKAII holoenzymes by interacting with
CC       regulatory subunit (R) of PKA, PRKAR1A/PKR1 and PRKAR2A/PKR2,
CC       respectively. Interacts with NFKB1, NFKB2 and NFKBIA in platelets;
CC       these interactions are disrupted by thrombin and collagen. Binds
CC       to ABL1 in spermatozoa and with CDC25B in oocytes. Interacts with
CC       APOBEC3G and AICDA. Interacts with RAB13; downstream effector of
CC       RAB13 involved in tight junction assembly.
CC       {ECO:0000269|PubMed:15096524, ECO:0000269|PubMed:16387847,
CC       ECO:0000269|PubMed:18836454, ECO:0000269|PubMed:20356841,
CC       ECO:0000269|PubMed:20732331, ECO:0000269|PubMed:21774789,
CC       ECO:0000269|PubMed:21812984}.
CC   -!- INTERACTION:
CC       Q9NQ31:AKIP1; NbExp=4; IntAct=EBI-476586, EBI-517035;
CC       P09917:ALOX5; NbExp=2; IntAct=EBI-476586, EBI-79934;
CC       P49841:GSK3B; NbExp=5; IntAct=EBI-476586, EBI-373586;
CC       Q5S007:LRRK2; NbExp=6; IntAct=EBI-476586, EBI-5323863;
CC       P10644:PRKAR1A; NbExp=3; IntAct=EBI-476586, EBI-476431;
CC       P12369:Prkar2b (xeno); NbExp=2; IntAct=EBI-476586, EBI-6096160;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Nucleus
CC       {ECO:0000250}. Mitochondrion {ECO:0000250}. Note=Translocates into
CC       the nucleus (monomeric catalytic subunit). The inactive holoenzyme
CC       is found in the cytoplasm. Distributed throughout the cytoplasm in
CC       meiotically incompetent oocytes. Associated to mitochondrion as
CC       meiotic competence is acquired. Aggregates around the germinal
CC       vesicles (GV) at the immature GV stage oocytes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell projection, cilium,
CC       flagellum. Note=Expressed in the midpiece region of the sperm
CC       flagellum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=C-alpha-1;
CC         IsoId=P17612-1; Sequence=Displayed;
CC       Name=2; Synonyms=C-alpha-2, C-alpha-S, C(s);
CC         IsoId=P17612-2; Sequence=VSP_004759;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is ubiquitous. Isoform 2 is sperm-
CC       specific and is enriched in pachytene spermatocytes but is not
CC       detected in round spermatids. {ECO:0000269|PubMed:10906071,
CC       ECO:0000269|PubMed:21812984}.
CC   -!- PTM: Asn-3 is partially deaminated to Asp giving rise to 2 major
CC       isoelectric variants, called CB and CA respectively.
CC       {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Phosphorylation is enhanced by vitamin
CC       K(2). Phosphorylated on threonine and serine residues.
CC       Phosphorylation on Thr-198 is required for full activity.
CC       {ECO:0000269|PubMed:12372837, ECO:0000269|PubMed:16765046,
CC       ECO:0000269|PubMed:17909264, ECO:0000269|PubMed:20137943,
CC       ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20732331,
CC       ECO:0000269|PubMed:21774789, ECO:0000269|Ref.37}.
CC   -!- PTM: Phosphorylated at Tyr-331 by activated receptor tyrosine
CC       kinases EGFR and PDGFR; this increases catalytic efficienncy.
CC       {ECO:0000250}.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 4
CC       (PPNAD4) [MIM:615830]: A rare bilateral adrenal defect causing
CC       ACTH-independent Cushing syndrome. Macroscopic appearance of the
CC       adrenals is characteristic with small pigmented micronodules
CC       observed in the cortex. Adrenal glands show overall normal size
CC       and weight, and multiple small yellow-to-dark brown nodules
CC       surrounded by a cortex with a uniform appearance. Microscopically,
CC       there are moderate diffuse cortical hyperplasia with mostly
CC       nonpigmented nodules, multiple capsular deficits and massive
CC       circumscribed and infiltrating extra-adrenal cortical excrescences
CC       with micronodules. Clinical manifestations of Cushing syndrome
CC       include facial and truncal obesity, abdominal striae, muscular
CC       weakness, osteoporosis, arterial hypertension, diabetes.
CC       {ECO:0000269|PubMed:24571724, ECO:0000269|PubMed:24700472,
CC       ECO:0000269|PubMed:24747643, ECO:0000269|PubMed:24855271}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. cAMP subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/prkaca/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X07767; CAA30597.1; -; mRNA.
DR   EMBL; AK290147; BAF82836.1; -; mRNA.
DR   EMBL; DQ667173; ABG25918.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84399.1; -; Genomic_DNA.
DR   EMBL; BC039846; AAH39846.1; -; mRNA.
DR   EMBL; BC108259; AAI08260.1; -; mRNA.
DR   EMBL; AF208004; AAG35720.1; -; mRNA.
DR   EMBL; AF239744; AAF76426.1; -; mRNA.
DR   EMBL; AF224718; AAF75622.1; -; mRNA.
DR   CCDS; CCDS12304.1; -. [P17612-1]
DR   CCDS; CCDS12305.1; -. [P17612-2]
DR   PIR; S01404; OKHU2C.
DR   RefSeq; NP_001291278.1; NM_001304349.1.
DR   RefSeq; NP_002721.1; NM_002730.3. [P17612-1]
DR   RefSeq; NP_997401.1; NM_207518.2. [P17612-2]
DR   UniGene; Hs.631630; -.
DR   PDB; 2GU8; X-ray; 2.20 A; A=15-351.
DR   PDB; 3AGL; X-ray; 2.10 A; A/B=1-351.
DR   PDB; 3AGM; X-ray; 2.00 A; A=1-351.
DR   PDB; 3AMA; X-ray; 1.75 A; A=1-351.
DR   PDB; 3AMB; X-ray; 2.25 A; A=1-351.
DR   PDB; 3L9L; X-ray; 2.00 A; A/B=1-351.
DR   PDB; 3L9M; X-ray; 1.90 A; A/B=1-351.
DR   PDB; 3L9N; X-ray; 2.00 A; A=1-351.
DR   PDB; 3MVJ; X-ray; 2.49 A; A/B/E=1-351.
DR   PDB; 3NX8; X-ray; 2.00 A; A=1-351.
DR   PDB; 3OOG; X-ray; 2.00 A; A=1-351.
DR   PDB; 3OVV; X-ray; 1.58 A; A=1-351.
DR   PDB; 3OWP; X-ray; 1.88 A; A=1-351.
DR   PDB; 3OXT; X-ray; 2.20 A; A=1-351.
DR   PDB; 3P0M; X-ray; 2.03 A; A=1-351.
DR   PDB; 3POO; X-ray; 1.60 A; A=1-351.
DR   PDB; 3VQH; X-ray; 1.95 A; A=1-351.
DR   PDB; 4AE6; X-ray; 2.10 A; A/B=16-351.
DR   PDB; 4AE9; X-ray; 2.30 A; A/B=16-351.
DR   PDB; 4WB5; X-ray; 1.64 A; A=2-351.
DR   PDB; 4WB6; X-ray; 2.10 A; A/B=2-351.
DR   PDB; 4WB7; X-ray; 1.90 A; A/B=16-351.
DR   PDB; 4WB8; X-ray; 1.55 A; A=16-351.
DR   PDBsum; 2GU8; -.
DR   PDBsum; 3AGL; -.
DR   PDBsum; 3AGM; -.
DR   PDBsum; 3AMA; -.
DR   PDBsum; 3AMB; -.
DR   PDBsum; 3L9L; -.
DR   PDBsum; 3L9M; -.
DR   PDBsum; 3L9N; -.
DR   PDBsum; 3MVJ; -.
DR   PDBsum; 3NX8; -.
DR   PDBsum; 3OOG; -.
DR   PDBsum; 3OVV; -.
DR   PDBsum; 3OWP; -.
DR   PDBsum; 3OXT; -.
DR   PDBsum; 3P0M; -.
DR   PDBsum; 3POO; -.
DR   PDBsum; 3VQH; -.
DR   PDBsum; 4AE6; -.
DR   PDBsum; 4AE9; -.
DR   PDBsum; 4WB5; -.
DR   PDBsum; 4WB6; -.
DR   PDBsum; 4WB7; -.
DR   PDBsum; 4WB8; -.
DR   ProteinModelPortal; P17612; -.
DR   SMR; P17612; 16-351.
DR   BioGrid; 111553; 116.
DR   DIP; DIP-33878N; -.
DR   IntAct; P17612; 59.
DR   MINT; MINT-95365; -.
DR   STRING; 9606.ENSP00000309591; -.
DR   BindingDB; P17612; -.
DR   ChEMBL; CHEMBL2094138; -.
DR   GuidetoPHARMACOLOGY; 1476; -.
DR   PhosphoSite; P17612; -.
DR   BioMuta; PRKACA; -.
DR   DMDM; 125205; -.
DR   MaxQB; P17612; -.
DR   PaxDb; P17612; -.
DR   PRIDE; P17612; -.
DR   DNASU; 5566; -.
DR   Ensembl; ENST00000308677; ENSP00000309591; ENSG00000072062.
DR   Ensembl; ENST00000589994; ENSP00000466651; ENSG00000072062. [P17612-2]
DR   GeneID; 5566; -.
DR   KEGG; hsa:5566; -.
DR   UCSC; uc002myb.3; human. [P17612-2]
DR   UCSC; uc002myc.3; human. [P17612-1]
DR   CTD; 5566; -.
DR   GeneCards; GC19M014202; -.
DR   HGNC; HGNC:9380; PRKACA.
DR   HPA; CAB010361; -.
DR   MIM; 601639; gene.
DR   MIM; 615830; phenotype.
DR   neXtProt; NX_P17612; -.
DR   Orphanet; 401920; Fibrolamellar hepatocellular carcinoma.
DR   PharmGKB; PA33748; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00790000122941; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P17612; -.
DR   KO; K04345; -.
DR   OMA; NAATANK; -.
DR   OrthoDB; EOG7VX8WD; -.
DR   PhylomeDB; P17612; -.
DR   TreeFam; TF313399; -.
DR   BRENDA; 2.7.11.11; 2681.
DR   Reactome; REACT_1520; Gluconeogenesis.
DR   Reactome; REACT_1525; PKA-mediated phosphorylation of key metabolic factors.
DR   Reactome; REACT_15296; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; REACT_15334; DARPP-32 events.
DR   Reactome; REACT_15364; Loss of Nlp from mitotic centrosomes.
DR   Reactome; REACT_15451; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; REACT_15497; PKA-mediated phosphorylation of CREB.
DR   Reactome; REACT_15530; PKA activation.
DR   Reactome; REACT_160315; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; REACT_18274; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; REACT_18325; Regulation of insulin secretion.
DR   Reactome; REACT_1946; PKA activation in glucagon signalling.
DR   Reactome; REACT_20625; CREB phosphorylation through the activation of Adenylate Cyclase.
DR   Reactome; REACT_23837; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; REACT_23898; Rap1 signalling.
DR   Reactome; REACT_24023; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; REACT_24970; Factors involved in megakaryocyte development and platelet production.
DR   Reactome; REACT_264464; VEGFA-VEGFR2 Pathway.
DR   Reactome; REACT_267700; Degradation of GLI2 by the proteasome.
DR   Reactome; REACT_267965; Anchoring of the basal body to the plasma membrane.
DR   Reactome; REACT_268156; Degradation of GLI1 by the proteasome.
DR   Reactome; REACT_268323; Hedgehog 'off' state.
DR   Reactome; REACT_268366; GLI3 is processed to GLI3R by the proteasome.
DR   Reactome; REACT_355503; CD209 (DC-SIGN) signaling.
DR   Reactome; REACT_494; Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis.
DR   SignaLink; P17612; -.
DR   ChiTaRS; PRKACA; human.
DR   EvolutionaryTrace; P17612; -.
DR   GeneWiki; PRKACA; -.
DR   GenomeRNAi; 5566; -.
DR   NextBio; 21564; -.
DR   PRO; PR:P17612; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P17612; -.
DR   CleanEx; HS_PRKACA; -.
DR   ExpressionAtlas; P17612; baseline and differential.
DR   Genevisible; P17612; HS.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0034704; C:calcium channel complex; TAS:BHF-UCL.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; NAS:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0031514; C:motile cilium; IEA:UniProtKB-KW.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0097225; C:sperm midpiece; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004691; F:cAMP-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034237; F:protein kinase A regulatory subunit binding; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; TAS:BHF-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; TAS:BHF-UCL.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; TAS:BHF-UCL.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:UniProtKB.
DR   GO; GO:0071374; P:cellular response to parathyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0051480; P:cytosolic calcium ion homeostasis; TAS:BHF-UCL.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:Reactome.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0051447; P:negative regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:1901621; P:negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006996; P:organelle organization; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; IDA:UniProtKB.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; TAS:BHF-UCL.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; TAS:BHF-UCL.
DR   GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl.
DR   GO; GO:0002027; P:regulation of heart rate; TAS:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0045667; P:regulation of osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; TAS:BHF-UCL.
DR   GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl.
DR   GO; GO:0060314; P:regulation of ryanodine-sensitive calcium-release channel activity; TAS:BHF-UCL.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0048240; P:sperm capacitation; ISS:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0019433; P:triglyceride catabolic process; TAS:Reactome.
DR   GO; GO:0006833; P:water transport; TAS:Reactome.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; cAMP; Cell membrane;
KW   Cell projection; Cilium; Complete proteome; Cushing syndrome;
KW   Cytoplasm; Disease mutation; Flagellum; Kinase; Lipoprotein; Membrane;
KW   Mitochondrion; Myristate; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P00517}.
FT   CHAIN         2    351       cAMP-dependent protein kinase catalytic
FT                                subunit alpha.
FT                                /FTId=PRO_0000086052.
FT   DOMAIN       44    298       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      299    351       AGC-kinase C-terminal.
FT   NP_BIND      50     58       ATP.
FT   NP_BIND     122    128       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     169    172       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    167    167       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      73     73       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       3      3       Deamidated asparagine. {ECO:0000250}.
FT   MOD_RES      11     11       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES      49     49       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   MOD_RES     140    140       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P05132}.
FT   MOD_RES     196    196       Phosphothreonine.
FT                                {ECO:0000269|PubMed:12372837}.
FT   MOD_RES     198    198       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:12372837,
FT                                ECO:0000269|PubMed:16765046,
FT                                ECO:0000269|PubMed:20137943,
FT                                ECO:0000269|PubMed:20481595,
FT                                ECO:0000269|PubMed:20732331,
FT                                ECO:0000269|PubMed:21774789,
FT                                ECO:0000269|Ref.37}.
FT   MOD_RES     202    202       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17909264}.
FT   MOD_RES     331    331       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P05132}.
FT   MOD_RES     339    339       Phosphoserine.
FT                                {ECO:0000269|PubMed:16765046,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20137943,
FT                                ECO:0000269|PubMed:20481595,
FT                                ECO:0000269|PubMed:20732331,
FT                                ECO:0000269|PubMed:21774789,
FT                                ECO:0000269|PubMed:24275569,
FT                                ECO:0000269|Ref.37}.
FT   LIPID         2      2       N-myristoyl glycine. {ECO:0000250}.
FT   VAR_SEQ       1     15       MGNAAAAKKGSEQES -> MASNSSD (in isoform
FT                                2). {ECO:0000303|PubMed:10841548,
FT                                ECO:0000303|PubMed:10906071,
FT                                ECO:0000303|PubMed:10982398}.
FT                                /FTId=VSP_004759.
FT   VARIANT      41     41       L -> V (in dbSNP:rs56029020).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040591.
FT   VARIANT      46     46       R -> Q (in dbSNP:rs56085217).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040592.
FT   VARIANT     206    206       L -> R (in PPNAD4; somatic mutation; the
FT                                mutation results in cAMP-independent
FT                                basal protein kinase activity and
FT                                constitutive activation of protein kinase
FT                                A). {ECO:0000269|PubMed:24571724,
FT                                ECO:0000269|PubMed:24700472,
FT                                ECO:0000269|PubMed:24747643,
FT                                ECO:0000269|PubMed:24855271}.
FT                                /FTId=VAR_071707.
FT   VARIANT     264    264       S -> C (in dbSNP:rs35635531).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040593.
FT   MUTAGEN      48     48       K->R: Enhanced basal kinase activity;
FT                                when associated with Q-96, L-121, A-124,
FT                                K-182 and A-184.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN      96     96       L->Q: Enhanced basal kinase activity;
FT                                when associated with R-48, L-121, A-124,
FT                                K-182 and A-184.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN     121    121       M->L: Enhanced basal kinase activity;
FT                                when associated with R-48, Q-96, A-124,
FT                                K-182 and A-184.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN     124    124       V->A: Enhanced basal kinase activity;
FT                                when associated with R-48, Q-96, L-121,
FT                                K-182 and A-184.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN     182    182       Q->K: Enhanced basal kinase activity;
FT                                when associated with R-48, Q-96, L-121,
FT                                A-124 and A-184.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN     184    184       T->A: Enhanced basal kinase activity;
FT                                when associated with R-48, Q-96, L-121,
FT                                A-124 and K-182.
FT                                {ECO:0000269|PubMed:21774789}.
FT   MUTAGEN     195    195       R->A: No phosphorylation.
FT                                {ECO:0000269|PubMed:12372837}.
FT   MUTAGEN     201    201       G->A: No phosphorylation.
FT                                {ECO:0000269|PubMed:12372837}.
FT   MUTAGEN     202    202       T->A: No phosphorylation.
FT                                {ECO:0000269|PubMed:12372837}.
FT   MUTAGEN     205    205       Y->A: Loss of allosteric regulation.
FT                                {ECO:0000269|PubMed:18178622}.
FT   HELIX         3      6       {ECO:0000244|PDB:3AMA}.
FT   HELIX        16     32       {ECO:0000244|PDB:4WB8}.
FT   HELIX        41     43       {ECO:0000244|PDB:4WB8}.
FT   STRAND       44     52       {ECO:0000244|PDB:4WB8}.
FT   STRAND       57     63       {ECO:0000244|PDB:4WB8}.
FT   TURN         64     66       {ECO:0000244|PDB:4WB8}.
FT   STRAND       69     76       {ECO:0000244|PDB:4WB8}.
FT   HELIX        77     82       {ECO:0000244|PDB:4WB8}.
FT   HELIX        86     98       {ECO:0000244|PDB:4WB8}.
FT   STRAND      107    112       {ECO:0000244|PDB:4WB8}.
FT   STRAND      114    122       {ECO:0000244|PDB:4WB8}.
FT   HELIX       129    136       {ECO:0000244|PDB:4WB8}.
FT   HELIX       141    160       {ECO:0000244|PDB:4WB8}.
FT   HELIX       170    172       {ECO:0000244|PDB:4WB8}.
FT   STRAND      173    175       {ECO:0000244|PDB:4WB8}.
FT   STRAND      181    183       {ECO:0000244|PDB:4WB8}.
FT   HELIX       203    205       {ECO:0000244|PDB:4WB8}.
FT   HELIX       208    211       {ECO:0000244|PDB:4WB8}.
FT   STRAND      212    214       {ECO:0000244|PDB:3L9M}.
FT   HELIX       219    234       {ECO:0000244|PDB:4WB8}.
FT   HELIX       244    253       {ECO:0000244|PDB:4WB8}.
FT   HELIX       264    273       {ECO:0000244|PDB:4WB8}.
FT   TURN        278    280       {ECO:0000244|PDB:4WB8}.
FT   TURN        282    284       {ECO:0000244|PDB:4AE9}.
FT   TURN        286    289       {ECO:0000244|PDB:4WB8}.
FT   HELIX       290    293       {ECO:0000244|PDB:4WB8}.
FT   HELIX       296    298       {ECO:0000244|PDB:4WB8}.
FT   HELIX       303    307       {ECO:0000244|PDB:4WB8}.
FT   TURN        345    350       {ECO:0000244|PDB:4WB8}.
SQ   SEQUENCE   351 AA;  40590 MW;  BF6D3ECD2614E5AB CRC64;
     MGNAAAAKKG SEQESVKEFL AKAKEDFLKK WESPAQNTAH LDQFERIKTL GTGSFGRVML
     VKHKETGNHY AMKILDKQKV VKLKQIEHTL NEKRILQAVN FPFLVKLEFS FKDNSNLYMV
     MEYVPGGEMF SHLRRIGRFS EPHARFYAAQ IVLTFEYLHS LDLIYRDLKP ENLLIDQQGY
     IQVTDFGFAK RVKGRTWTLC GTPEYLAPEI ILSKGYNKAV DWWALGVLIY EMAAGYPPFF
     ADQPIQIYEK IVSGKVRFPS HFSSDLKDLL RNLLQVDLTK RFGNLKNGVN DIKNHKWFAT
     TDWIAIYQRK VEAPFIPKFK GPGDTSNFDD YEEEEIRVSI NEKCGKEFSE F
//
